HX V2 O5 Nanocatalysts Combined with Ultrasound for Triple Amplification of Oxidative Stress to Enhance Cancer Catalytic Therapy

Angew Chem Int Ed Engl. 2022 Sep 26;61(39):e202208849. doi: 10.1002/anie.202208849. Epub 2022 Aug 25.

Abstract

Multiple amplification of tumor oxidative stress has been demonstrated as efficient strategy to enhance the reactive oxygen species (ROS)-mediated cancer therapy. Herein, vanadium-based nanocatalysts, hydrogen vanadium bronzes (HX V2 O5 , for short HVO), were constructed and employed as novel biocatalysts for amplifying tumor oxidative stress and enhancing cancer catalytic therapy. Such HVO nanocatalysts harboring multivalent V element possessed multi-functional catalytic activity in decomposing H2 O2 into ⋅OH and depleting endogenous glutathione (GSH) to dually amplify tumor oxidative stress. Meanwhile, HVO nanocatalysts could also be activated by ultrasound to further triply amplify oxidative stress. The massive intracellular ROS caused mitochondrial dysfunction, DNA damage, cell cycle arrest, and cell proliferation inhibition, further realizing cancer cell death and tumor growth inhibition. Collectively, HVO nanocatalysts highlight the remarkable value of ROS-mediated cancer therapies.

Keywords: Catalytic Therapy; HVO Nanocatalysts; Oxidative Stress; ROS Amplification; Sonodynamic Therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Glutathione / metabolism
  • Humans
  • Hydrogen
  • Neoplasms* / therapy
  • Oxidative Stress
  • Reactive Oxygen Species / metabolism
  • Vanadium*

Substances

  • Reactive Oxygen Species
  • Vanadium
  • Hydrogen
  • Glutathione